ArticleNeuro-oncology advances
Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review.Journal of neuropathology and experimental neurology · 2025Pooled it
- Prognostic Markers in Meningioma: Effectiveness of FISH-Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease-Specific Survival.Neuropathology and applied neurobiology · 2026Article
- Immunohistochemical Loss of MTAP as a Diagnostic and Prognostic Surrogate ofDiagnostics (Basel, Switzerland) · 2026Review
- Meningioma with trabecular architecture: a harbinger of BAP1 deficiency.Brain tumor pathology · 2026Article
- Giant Right Sphenoid Wing Meningioma as a Reversible Frontal Network Lesion: A Pseudo-bvFTD Case with Venous-Sparing Skull-Base Resection.Diagnostics (Basel, Switzerland) · 2026Article
- MRI and Meningioma Research: Hotspots and Trends via Bibliometric AnalysisCurrent medical imaging · 2026Article
- Challenging CDKN2A assessment in BRAF-altered gliomas: lessons from a pleomorphic xanthoastrocytoma-enriched cohort.Acta neuropathologica communications · 2025Article
- Pitfalls in the evaluation of CDKN2A copy number status in meningioma.Journal of neuro-oncology · 2025Article
- The prognostic value of H3 K27me3 in meningiomas: A review on current evidence and methodological challenges.Histology and histopathology · 2025Review
- Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.AJNR. American journal of neuroradiology · 2025Review
- EZH2 overexpression is associated with aggressive behavior and promotes cell proliferation in CNS WHO grade 3 meningiomas.Neuro-oncology advancesArticle
- Concordance of fluorescence in situ hybridization, whole-exome sequencing, and chromosomal microarray for evaluating high-risk molecular features in meningiomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The World Health Organization 2021 classification introduces molecular grading criteria for anaplastic meningiomas, including Methods: Clinical and histopathological information was obtained from the electronic medical records of grade 3 meningiomas resected at a tertiary center between 2007 and 2020. Molecular testing for Results: Eight of 15 cases demonstrated elevated mitotic index (≥20 mitoses per 10 consecutive high-power fields), 1 tumor exhibited BAP1 loss, 4 harbored Conclusions: Molecular alterations of grade 3 meningiomas stratify clinical outcomes more so than histologic features alone. Immunohistochemical loss of p16 and MTAP show promise in predicting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.